This measure evaluates the percentage of patients aged 18 years and older with chronic kidney disease (CKD) stages 2 and 3 who are prescribed an SGLT2 inhibitor during the measurement period. The goal is to increase the use of SGLT2 inhibitors, which have been shown to slow the progression of CKD and reduce cardiovascular events in this population.